Skip to main content
Understanding Nicotine Pharmacokinetics and Key Considerations for Designing Nonclinical Studies in Substance Use Disorder
Understanding Nicotine Pharmacokinetics and Key Considerations for Designing Nonclinical Studies in Substance Use Disorder

Understanding Nicotine Pharmacokinetics and Key Considerations for Designing Nonclinical Studies in Substance Use Disorder

Learn how pharmacokinetics, absorption, & behavioral data shape study designs and substance use risk assessments of nicotine delivery products in…
READ FULL BLOG
Choosing the Right Ophthalmic Development Strategy: Leading AMD and DME Therapies, Their PK Profiles, and What Efficacy Tells Us
Choosing the Right Ophthalmic Development Strategy: Leading AMD and DME Therapies, Their PK Profiles, and What Efficacy Tells Us

Choosing the Right Ophthalmic Development Strategy: Leading AMD and DME Therapies, Their PK Profiles, and What Efficacy Tells Us

Explore how PK profiles of AMD and DME therapies guide ophthalmic drug development strategy and anti-VEGF dosing in our blog:
READ FULL BLOG
Model-Informed Drug Development and the Shift Toward Fewer Trials and Reduced Toxicology Testing
Model-Informed Drug Development and the Shift Toward Fewer Trials and Reduced Toxicology Testing

Model-Informed Drug Development and the Shift Toward Fewer Trials and Reduced Toxicology Testing

Model-Informed Drug Development (MIDD) is reshaping regulation. Learn how ICH M15 and FDA flexibility are reducing Phase 3 trial requirements:
READ FULL BLOG
Antibiotic Resistance: Why We Need New Antibiotics
Antibiotic Resistance: Why We Need New Antibiotics

Antibiotic Resistance: Why We Need New Antibiotics

Antibiotic resistance is accelerating worldwide, driven by multidrug-resistant gram-negative bacteria and a limited pipeline of new therapies. Learn more:
READ FULL BLOG
Choosing the Right ADA Assay for Ocular Biologics: Ligand Binding vs. Cell-Based Assays
Choosing the Right ADA Assay for Ocular Biologics: Ligand Binding vs. Cell-Based Assays

Choosing the Right ADA Assay for Ocular Biologics: Ligand Binding vs. Cell-Based Assays

For ophthalmic biologics and gene therapies administered by intravitreal injection, understanding immunogenicity is critical. These therapies can trigger an immune…
READ FULL BLOG
Understanding the Four Key Disciplines Behind Nonclinical PK Studies
Understanding the Four Key Disciplines Behind Nonclinical PK Studies

Understanding the Four Key Disciplines Behind Nonclinical PK Studies

When it comes to bringing new therapies from concept to initial clinical trials, understanding how a drug behaves in the…
READ FULL BLOG
2025 Drug Development Trends: The Evolution of Innovation – A Xyzagen Industry Forecast
2025 Drug Development Trends: The Evolution of Innovation – A Xyzagen Industry Forecast

2025 Drug Development Trends: The Evolution of Innovation – A Xyzagen Industry Forecast

The drug development landscape is currently undergoing a major transformation, driven by advanced modeling, real-time bioanalysis, and cutting-edge therapeutic strategies.…
READ FULL BLOG
Welcome to Xyzagen: Your Partner in Early Drug Development and Beyond
Welcome to Xyzagen: Your Partner in Early Drug Development and Beyond

Welcome to Xyzagen: Your Partner in Early Drug Development and Beyond

Xyzagen is a boutique, client-focused, consulting and contract research organization (CRO), providing integrated support across the full spectrum of drug…
READ FULL BLOG
CONTACT US

Learn How We Can Become Your Virtual Discovery and PK Group

Our team is here to assist. Complete the form and we’ll be in touch shortly.

480 Hillsboro St., Ste 140 Pittsboro, NC 27312

LAB OPERATIONS: 919-726-2072

GENERAL INFO: [email protected]

BUSINESS DEV: [email protected]

Get in touch

Name(Required)

We are a proud registered supplier of scientist.com